| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tosedostat | CTRPv2 | pan-cancer | AAC | 0.0065 | 0.9 |
| mRNA | fingolimod | CTRPv2 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.9 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |